Quarry LP’s Charles River Laboratories CRL Stock Holding History

Quarry LP’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-125	Closed	-$19.6K	–	2225
2025 Q3	$19.6K	Buy	+125	New	+$19.9K	﹤0.01%	1427

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Quarry LP's CRL Position: Q4 2025 in Review

Quarry LP sold out of Charles River Laboratories (CRL) in Q4 2025, closing a stake of 125 shares — an estimated $19.6K sold.

Quarry LP first reported a position in CRL in Q3 2025 and held it in 1 quarter. The position peaked at $19.6K in Q3 2025. 580 funds tracked by Wall St. Rank hold CRL as of Q4 2025.

Quarry LP reported no remaining Charles River Laboratories position as of Q4 2025 after selling out during the quarter.
Quarry LP sold 125 Charles River Laboratories shares in Q4 2025, an estimated $19.6K.
Quarry LP first reported a position in Charles River Laboratories in Q3 2025 and held it in 1 quarter.
Quarry LP's Charles River Laboratories position peaked at $19.6K in Q3 2025.
580 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2025.

Based on Quarry LP's 13F filing for Q4 2025, filed 13 Feb 2026.